DDInter1423 DDInter899
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Pentobarbital {u} (Compound) resembles {v} (Compound) Thiopental
Pentobarbital {u} (Compound) binds {v} (Gene) GABRA5
Pentobarbital {u} (Compound) upregulates {v} (Gene) BUB1B
Pentobarbital {u} (Compound) downregulates {v} (Gene) GSTZ1
Pentobarbital {u} (Compound) causes {v} (Side Effect) Dizziness
Pentobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Pentobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracosactide
Pentobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clemastine
Pentobarbital {u} may lead to a major life threatening interaction when taken with {v} Morphine
Pentobarbital (Compound) resembles Thiopental (Compound)
Pentobarbital (Compound) binds GABRA5 (Gene)
Pentobarbital (Compound) upregulates BUB1B (Gene)
Pentobarbital (Compound) downregulates GSTZ1 (Gene)
Pentobarbital (Compound) causes Dizziness (Side Effect)
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Clemastine
Pentobarbital may lead to a major life threatening interaction when taken with Morphine